<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369456</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-09</org_study_id>
    <nct_id>NCT04369456</nct_id>
  </id_info>
  <brief_title>Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients</brief_title>
  <acronym>PredictCovidT</acronym>
  <official_title>Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-CoV-2 induces over-production of inflammatory cytokines, and especially interleukin-6
      (IL-6). The apparently strong association between blood levels of inflammaory cytokines and
      SARS-CoV-2 disease severity has led clinicians to evaluate the administration of steroids or
      anti-IL-6 antagonists in severely ill patients. As of this day, biomarkers capable of
      predicting clinical disease progression in Covid-19 patients with mild-to-moderate symptoms
      have not yet been formally identified. Identifying such markers and evaluating their
      predictive value may be exploited to guide patient care management, and as such forms the
      core objective of this proposal.

      Because of strong inter-individual variations in the ability of innate immune cells to
      produce cytokines, the hypothesis formulate and intend to test is that innate IL-6
      responsiveness varies between recently infected Covid-19 patients and could predict disease
      outcome.

      To test this hypothesis, the investigator propose to follow recently infected kidney
      transplant patients with moderate Covid-19 symptoms. These patients stand a higher risk to
      progress to severe disease. The staff plan to collect a blood sample in these patients using
      a system whereby ex vivo cytokine production is initiated in the very same blood collection
      tube without prior separation and centrifugation, thus reducing labour and operator bias.
      After incubation with or without known innate immune stimuli, the cell-free phase from each
      collection-culture tube will be assayed for IL-6 content. Associations between IL-6 content
      and disease outcome (encephalopathy, transfer to acute care or death) will be determined in
      115 Covid-19 kidney transplant patients with moderate symptoms followed in 9 centers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">October 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation</measure>
    <time_frame>10 months</time_frame>
    <description>quantity of IL-6 in of whole blood samples after ex vivo co-stimulation with LPS and ATP in Covid-19 kidney transplant patients.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Covid-19 kidney transplant patients with moderate symptoms</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms</description>
    <arm_group_label>Covid-19 kidney transplant patients with moderate symptoms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney or kidney-pancreas or kidney-heart transplant patients;

          -  SARS-CoV-2 positive (RT-PCR);

          -  COVID-19 symptoms at least once over a 8-day period preceding inclusion;

          -  Hospitalized or outpatients in one of the study centers: CHU de Nice, CHU de
             Strasbourg, Hôpital Necker (APHP), Hôpital Kremlin Bicêtre (APHP), Hôpital
             Pitié-Salpétriêre (APHP), Hospices Civils de Lyon, CHU de Saint-Etienne, CHU de
             Montpellier, Hôpital La Conception (APHM);

          -  Age &gt; 18 years;

          -  Free and informed consent.

        Exclusion Criteria:

          -  Age &gt; 85 years ;

          -  Kidney-liver transplant patients;

          -  Onset of symptoms (fever and/or cough) for more than 8 days;

          -  Acute respiraytory distress despite oxygen therapy, 02 ≥ 4L/min, arterial pressure &lt;
             85/55 mmHg or hemodynamic instability at time of inclusion, encephalopathy with
             Glasgow coma scale &lt; 14;

          -  Treatment with non-steroids anti-inflammatory agents within the last 14 days preceding
             onset of symptoms;

          -  Active bacterial or fungal infection documented at inclusion;

          -  Pregnancy;

          -  Under guardianship or curatorship;

          -  Non-affiliated person with Social Security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine SICARD</last_name>
    <phone>33 4 92 03 79 18</phone>
    <email>sicard.a@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>cynthia CAILLON</last_name>
    <phone>33 492 03 45 89</phone>
    <email>caillon.c@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lyon Univerity Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier THAUNAT</last_name>
      <email>olivier.thaunat@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier THAUNAT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie MOAL</last_name>
      <email>vmoal@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>valerie MOAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moglie Le Quintrec</last_name>
      <email>m-lequintrec-donnette@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Moglie Le Quintrec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine SICARD</last_name>
      <phone>334.92.03.79.18</phone>
      <email>sicard.a@chu-nice.Fr</email>
    </contact>
    <investigator>
      <last_name>Jean DELLAMONICA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine SICARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa DEMONCHY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara SEITZ-POLSKI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alexandre HERTIG</last_name>
      <email>alexandre.herig@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre HERTIG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dany ANGLICHEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud SNANOUDJ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Etienne University Hospital</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>christophe MARIAT</last_name>
      <email>mariat.c@chu-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe MARIAT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strasbourg Univeristy Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sophie Caillard Ohlmann</last_name>
      <email>sophie.caillard@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>sophie Caillard Ohlmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

